Internal Medicine, Endocrinology, Diabetes, & Metabolism · Monroe, MI
NPI
1669478681
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
15506 S Telegraph Rd
Monroe, MI, 48161
Phone (734) 682-5243
Groups this clinician bills Medicare through
Medicare paid, 2024
$199K
3,131 services
Medicare patients, 2024
798
Average age 69
Drug cost, 2024
$4.2M
13,550 prescriptions
Company payments, 2025
$2,323
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mahmood F Moosa was code 99214 (office e&m - established), 1,556 times for 699 patients. In total Mahmood F Moosa billed 3,131 services in 6 codes, and Medicare paid $199K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-01-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,556 | 699 | $83.54 | $130K |
| 83036 Blood Count | Office | 649 | 326 | $9.42 | $6,114 |
| 95251 Test - Miscellaneous | Office | 515 | 235 | $24.84 | $13K |
| 99215 Office E&M - Established | Office | 215 | 147 | $118.90 | $26K |
| 99205 Office E&M - New | Office | 141 | 141 | $156.13 | $22K |
| 99213 Office E&M - Established | Office | 55 | 47 | $53.15 | $2,923 |
By year: 2022 $226K for 3,699 services; 2023 $216K for 3,235 services; 2024 $199K for 3,131 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 649 | 326 | $9.42 | $6,114 |
Medicare prescription drug claims, 2024
In 2024, the drug Mahmood F Moosa prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,872 prescriptions and refills. In total Mahmood F Moosa wrote 13,550 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,872 | 3,601 | 487 | $17K |
| Metformin Hcl Generic | 715 | 1,402 | 201 | $4,321 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 504 | 928 | 186 | $122K |
| Glipizide Generic | 492 | 994 | 166 | $7,420 |
| Ozempic Semaglutide | 467 | 677 | 151 | $609K |
| Novolog Flexpen Insulin Aspart | 352 | 572 | 154 | $116K |
| Methimazole Generic | 313 | 570 | 84 | $2,940 |
| Liothyronine Sodium Generic | 283 | 519 | 83 | $11K |
| Atorvastatin Calcium Generic | 278 | 613 | 77 | $2,555 |
| Tresiba Flextouch U-100 Insulin Degludec | 246 | 436 | 81 | $205K |
| Humalog Kwikpen U-100 Insulin Lispro | 227 | 480 | 102 | $107K |
| Synthroid Levothyroxine Sodium | 214 | 482 | 62 | $10K |
| Trulicity Dulaglutide | 213 | 308 | 73 | $295K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 207 | 449 | 85 | $29K |
| Nateglinide Generic | 198 | 327 | 66 | $7,134 |
Brand drugs: 5,680 claims; generic drugs: 6,342 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mahmood F Moosa $2,323 ($2,323 in general payments such as food, travel and fees) from 30 companies. The largest payer was Amgen Inc. with $245.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 15 | $245 |
| Novo Nordisk Inc NVO | 12 | $208 |
| Lilly USA, LLC LLY | 14 | $200 |
| Ascendis Pharma Endocrinology Inc ASND | 9 | $161 |
| Dexcom, Inc. DXCM | 8 | $142 |
| Ascensia Diabetes Care Us Inc. | 6 | $127 |
| Sequel Med Tech, LLC | 6 | $119 |
| Mannkind Corporation MNKD | 4 | $106 |
| Recordati_rare_diseases_inc. | 5 | $96.16 |
| Xeris Pharmaceuticals, Inc. | 4 | $94.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.